We compared the prevalence of different criteria for metabolic Triclabendazole syndrome and the levels of respective parameters in 38 patients that never had surgical intervention and versus 42 patients that already had at least one surgical intervention. There were no significant differences in sex, age, and duration of disease between these two groups. As expected, the Sartorius score was lower in the post-operative group as compared to the preoperative group. However, no differences for any of the criteria for the metabolic syndrome between both groups could be detected. To substantiate this finding, we analyzed details about further 12 patients who had their last surgical intervention averagely 4 years ago. Although these patients had no or minimal disease activity, their current BMI had remained unchanged compared to values before surgery. All these data suggest that the inflammation present in AI patients does not have any major impact on their metabolic alterations. In the last part of our study we questioned which AI patients are particularly Terutroban endangered by the metabolic syndrome. The frequency of the metabolic syndrome usually increases with increasing age of a population. Surprisingly, we found no significant correlation between the patients�� age and the number of fulfilled metabolic syndrome criteria or between the age and respective parameter levels even if such correlations clearly existed in our control population. Accordingly, the prevalence of central obesity, hypo-HDL-cholesterolemia, hypertriglyceridemia, and hyperglycemia was also significantly elevated in AI patients. Finally, the average waist circumference, plasma TG levels, fasting plasma glucose levels, as well as the systolic and diastolic blood pressure were significant higher, and average plasma HDL levels were lower in AI patients than in control participants. Increased prevalence of the metabolic syndrome is also known from patients suffering from some other chronic inflammatory diseases, e.g., psoriasis. However, there seem to be certain differences between psoriasis and AI in this regard. First, the prevalence of metabolic disturbances and metabolic syndrome in AI patients appears to be higher than in psoriasis patients. For example, Love et al. very recently showed for populations of psoriasis patients and controls, which, regarding age and sex, were comparable to our cohort, a prevalence of metabolic syndrome of 31.4% and 17.1%, respectively, and an odds ratio of 2.22. Second, in psoriasis but not in AI patients there was an association between disease duration and metabolic syndrome appearance and between at least some criteria of the metabolic syndrome and the severity of the disease. Third, the metabolic syndrome preferentially affects psoriasis patients at a mostly higher age, whereas many young AI patients are concerned.